BRAF

Biomarkers

BRAF is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
BRAF p.V600E	Somatic Variant	19	49
BRAF p.V600K	Somatic Variant	11	27
v::BRAF	Rearrangement	1	1
BRAF rearrangements	Rearrangement	1	1

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib
Sensitivity (+)	BRAF p.V600E	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib
Sensitivity (+)	BRAF p.V600K	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib
Sensitivity (+)	BRAF rearrangements	Low-Grade Glioma, NOS	Tovorafenib
Sensitivity (+)	v::BRAF	Low-Grade Glioma, NOS	Tovorafenib
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib
Sensitivity (+)	BRAF p.V600K	Low-Grade Glioma, NOS	Tovorafenib
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Vemurafenib